Categories AlphaGraphs, Earnings, Technology
ORCL Earnings: Oracle Q2 2026 adjusted profit beats estimates
Technology giant Oracle Corporation (NYSE: ORCL) on Wednesday reported higher revenues and adjusted earnings for the second quarter of 2026. Earnings topped expectations.
Total revenues increased to $16.10 billion in the November quarter from $14.06 billion in the same period a year earlier, missing Wall Street’s estimates. Adjusted earnings, excluding one-off items, were $2.26 per share in the second quarter, compared to $1.47 per share in Q2 2025. The bottom line came in above forecasts.
On a reported basis, the company posted a net income of $6.14 billion or $2.10 per share for Q2, compared to $3.15 billion or $1.10 per share in the year-ago quarter.
“For years, Oracle has been investing in AI and building autonomous cloud software. Oracle’s Autonomous Database and Autonomous Linux have been key to reducing human labor and human error in our datacenters. Because our datacenters are highly automated, we can build and run more of them,” said Oracle’s CEO, Clay Magouyrk.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
After a rollercoaster year, is Tesla (TSLA) stock a good bet?
In recent years, Tesla's (NASDAQ: TSLA) stock has often swung between record highs and sharp corrections, reflecting shifts in investor sentiment, broader economic conditions, and changes in its financial performance.
Dollar Tree (DLTR), Dollar General (DG): Discount stores remain key gainers in a value-conscious landscape
Discount retailers Dollar Tree, Inc. (NASDAQ: DLTR) and Dollar General Corporation (NYSE: DG) have seen their stocks gain more than 30% in the past three months. The dollar stores continue
Everything you need to know about Aktis Oncology’s upcoming IPO
IPO activity in 2025 showed a marked rebound, led by the technology and healthcare sectors, after last year's sluggish performance. Aktis Oncology, which develops radiopharmaceuticals for solid tumors, is the
